|
[Related PubMed/MEDLINE]
Total Number of Papers: 26
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: TOT |
| Long Form |
: time on treatment |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country. |
ALK, NCTSD, NSCLC, OS |
| 2 |
2022 |
Application of several machine learning algorithms for the prediction of afatinib treatment outcome in advanced-stage EGFR-mutated non-small-cell lung cancer. |
AUC, KM, ML, OS |
| 3 |
2022 |
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation. |
PMMTB, SOC |
| 4 |
2022 |
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective. |
AEs, AML, CR, CRi, DSA, EFS, HRU, ICERs, LY, OS, PSA, QALY, US |
| 5 |
2022 |
First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea. |
CI, EGFR, NSCLCs, OS |
| 6 |
2022 |
The Prognostic Impact of Radiotherapy Delays in Oropharynx Carcinoma and the Role of p16 Status. |
CI, CSS, HR, LRR, RT, TDs |
| 7 |
2022 |
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22. |
CI, CNS, EGFR, KCSG, NSCLC, ORR, OS |
| 8 |
2021 |
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. |
mCRPC, NHAs, OS, US |
| 9 |
2021 |
Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer. |
GA, OS |
| 10 |
2021 |
Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes. |
HNSCC, HPV, ICB, non-OP, OPSCC, R/M, rwOS |
| 11 |
2021 |
Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer. |
COPE, NNT, NSCLC, OS, PD-L1, PFS, RMST |
| 12 |
2021 |
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. |
CI, HR, ICIs, mUC, OS, OS |
| 13 |
2021 |
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea. |
CI, EGFR, NSCLC, OS, TKIs |
| 14 |
2020 |
A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England. |
CE, DCF, LTTACC, MBG, MEAs, NMB, PSUB, SDM, VOI |
| 15 |
2020 |
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. |
EGFR, NSCLC, QALMs |
| 16 |
2020 |
Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. |
GEM, nab-P, OS, PDAC, PFS |
| 17 |
2020 |
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. |
mUC, OS, PFS, QALYs |
| 18 |
2019 |
Intensity Modulated Radiation Therapy Versus Volumetric Arc Radiation Therapy in the Treatment of Glioblastoma-Does Clinical Benefit Follow Dosimetric Advantage? |
GBM, IMRT, VMAT |
| 19 |
2018 |
Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. |
aRCC, HRU, RCC |
| 20 |
2018 |
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. |
DFS, OS, SCOT |
| 21 |
2015 |
Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. |
CI, HR, MBC, OS, PFS |
| 22 |
2015 |
Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. |
MBC, NSAI, PFS, TTC |
| 23 |
2015 |
Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. |
CI, HR, MBC, OS, PFS |
| 24 |
2015 |
Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. |
CT, ET, EVE, HR, MBC, PFS |
| 25 |
2015 |
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. |
CI, HR, MBC |
| 26 |
2012 |
Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution. |
mCRPC, OS, PSA, TFI |
|
A Search Service for Abbreviation / Long Form
